Thursday, June 5, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Study shows nirsevimab provides significant protection against RSV

March 11, 2025
in Diseases
Reading Time: 2 mins read
0 0
A A
0
Home Diseases
Share on FacebookShare on Twitter


A examine from Yale College at the moment in JAMA Community Open reveals substantial safety by the preventive drug nirsevimab (Beyfortus) in opposition to toddler respiratory syncytial virus (RSV) infections, hospitalizations, and extreme illness.

The test-negative case-control examine used inpatient, outpatient, and emergency division information from the Yale New Haven Well being System to estimate efficacy of the RSV monoclonal antibody drug in 3,090 infants seen from October 1, 2023, to Could 9, 2024.

In whole there have been 680 RSV-positive circumstances (22.0%) and a pair of,410 RSV-negative controls (78.0%). RSV-positive sufferers had been barely youthful than RSV-negative sufferers, at 6.1 months versus 6.9 months. Nirsevimab uptake was 10.7% (330 sufferers). Of the RSV-positive sufferers, nirsevimab use was documented in 21 sufferers and in 309 RSV-negative controls.

Safety peaked at 2 weeks

Adjusted effectiveness of nirsevimab was 68.4% (95% confidence interval [CI]50.3% to 80.8%) in opposition to medically attended RSV an infection, 61.6% (95% CI, 35.6% to 78.6%) in opposition to outpatient visits, and 80.5% (95% CI, 52.0% to 93.5%) in opposition to hospitalizations.

In opposition to extreme RSV illness, nirsevimab had a really excessive efficacy of 84.6% (95% CI, 58.7% to 95.6%).

Safety in opposition to infections peaked at 2 weeks post-administration, when the antibody was estimated to be 79.3% efficient (95% CI, 63.4% to 90.6%). By 14 weeks, that share dropped to 54.8% (95% CI, 16.3% to 74.7%).

This sample of waning effectiveness was noticed throughout all scientific outcomes and was per information from scientific trials.

“This sample of waning effectiveness was noticed throughout all scientific outcomes and was per information from scientific trials,” the authors wrote.

Curiously, protecting effectiveness was noticed in opposition to all-cause decrease respiratory tract infections (LRTIs) (49.4%) and all-cause LRTI hospitalization (79.1%) through the peak months of RSV season (November and December 2023) when put next with different research, the authors stated.

“On condition that RSV was the predominant virus throughout these months (RSV positivity price, 39.3% in our pattern), these estimates largely mirror the effectiveness of nirsevimab in opposition to RSV,” the authors wrote.

The authors stated their findings help US pointers recommending nirsevimab for all infants getting into their first RSV season.



Source link

Tags: NirsevimabprotectionRSVshowsSignificantStudy
Previous Post

Former NIH director Francis Collins worries for his safety

Next Post

Avian flu detected in Belgian cats as outbreaks continue on US poultry, dairy farms

Related Posts

Baby’s microbiome may protect against later childhood viral infection
Diseases

Baby’s microbiome may protect against later childhood viral infection

June 5, 2025
Maternal obesity linked to increase in childhood infections
Diseases

Maternal obesity linked to increase in childhood infections

June 5, 2025
‘Helping people survive’: how creating a hip-hop album saved incarcerated artists | Hip-hop
Diseases

‘Helping people survive’: how creating a hip-hop album saved incarcerated artists | Hip-hop

June 4, 2025
Mother’s obesity linked to child’s heightened hospital admission risk for infection
Diseases

Mother’s obesity linked to child’s heightened hospital admission risk for infection

June 4, 2025
Report highlights evidence, remaining data gaps on vaccines and antibiotic resistance
Diseases

Report highlights evidence, remaining data gaps on vaccines and antibiotic resistance

June 3, 2025
MIS-C patients catch up with controls by most measures within 2 years, data suggest
Diseases

MIS-C patients catch up with controls by most measures within 2 years, data suggest

June 4, 2025
Next Post
Avian flu detected in Belgian cats as outbreaks continue on US poultry, dairy farms

Avian flu detected in Belgian cats as outbreaks continue on US poultry, dairy farms

Michael Gove ‘wanted to circumvent watchdog’ to push through Dyson bid, Covid inquiry told | Covid inquiry

Michael Gove ‘wanted to circumvent watchdog’ to push through Dyson bid, Covid inquiry told | Covid inquiry

#religion #oudh #food #oud #oudhhindi #chocolate #assamese #viralreels Assam Oudh wholesale market

#religion #oudh #food #oud #oudhhindi #chocolate #assamese #viralreels Assam Oudh wholesale market

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Exercise Motivation May Rely On Gut Health, Study Finds
Diet & Fitness

Exercise Motivation May Rely On Gut Health, Study Finds

by admin
June 4, 2025
0

Printed in Nature, the research investigated which inner elements—if any—affect our need to train. The researchers analyzed a variety of...

Prior COVID vaccination produces immune response against new SARS-CoV-2 strains, study finds

Prior COVID vaccination produces immune response against new SARS-CoV-2 strains, study finds

May 29, 2025
Guidance requiring hospitals to provide emergency abortions revoked

Guidance requiring hospitals to provide emergency abortions revoked

June 4, 2025
Coreline Soft scores imaging AI supply contracts with UK NHS, Boehringer Ingelheim and more briefs

Coreline Soft scores imaging AI supply contracts with UK NHS, Boehringer Ingelheim and more briefs

May 30, 2025
Lecture 04 – Environment PT365 (Value Added) | #currentaffairs #upsc2025 #upscprelims #xias

Lecture 04 – Environment PT365 (Value Added) | #currentaffairs #upsc2025 #upscprelims #xias

June 2, 2025
4 Notable Health Tech Funding Announcements in May

4 Notable Health Tech Funding Announcements in May

June 1, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In